Table 2.
Studies included in the meta‐analyses, 2013–2019 (overall survival)
| Author, year | Tumor type | Chemotherapy | Dosage | n | RDI comparison |
|---|---|---|---|---|---|
| Studies evaluating carboplatin‐based regimens for ovarian or breast cancer or NSCLC | |||||
| Bun 2019 [33] | Ovarian | Paclitaxel/carboplatin | PPaclitaxel (80 mg/m2 on days 1, 8, and 15) and carboplatin (AUC 6 mg/mL per minute on day 1) in a 21‐day cycle | 244 | <80% vs. ≥80% |
| Denduluri 2018 [5] | Ovarian | Paclitaxel/carboplatin | Carboplatin/paclitaxel every 3 weeks: 5 AUC/175 mg/m2 | 170 | <85% vs. ≥85% |
| Au‐Yeung 2014 [28] | Ovarian | Paclitaxel/carboplatin | Carboplatin AUC 5–6, paclitaxel 175 mg/m2 | 537 | <85% vs. ≥85% |
| Crawford 2020 [29] | NSCLC | Platinum‐based therapies: carboplatin/paclitaxel, pemetrexed/carboplatin, carboplatin/bevacizumab/paclitaxel, pemetrexed/cisplatin, carboplatin/pemetrexed/bevacizumab, carboplatin/gemcitabine |
Carboplatin + paclitaxel 5 AUC/175 mg/m2; Carboplatin + pemetrexed 5 AUC/500 mg/m2; Carboplatin + bevacizumab + paclitaxel 5 AUC/15 mg/kg/175 mg/m2; Pemetrexed + cisplatin 500 mg/m2/75 mg/m2; Carboplatin + pemetrexed + bevacizumab 5 AUC/500 mg/m2/15 mg/kg; Carboplatin + gemcitabine 5 AUC/1,000 mg/m2 × 2 (days 1 and 8) |
3,866 | <85% vs. ≥85% |
| Denduluri 2018 [5] | Breast | The most common chemotherapy regimens were paclitaxel/bevacizumab q4w, albumin‐bound paclitaxel q3w, and weekly paclitaxel |
Paclitaxel/bevacizumab every 4 weeks 240 mg/m2/30 mg/kg, six cycles; Albumin‐bound paclitaxel every 3 weeks 300 mg/m2, six cycles; Paclitaxel weekly 80 mg/m2, 25 cycles; Docetaxel every 3 weeks 75 mg/m2, eight cycles; Carboplatin/paclitaxel every 3 weeks 6 AUC/175 mg/m2, eight cycles; Vinorelbine weekly 25 mg/m2, 25 cycles; Carboplatin/paclitaxel every 4 weeks 6 AUC/240 mg/m2, six cycles |
874 | <85% vs. ≥85% |
| Studies evaluating FOLFOX, FOLFIRI, or FOLFIRINOX regimens in colorectal or pancreatic cancer | |||||
| Nakayama 2014 [25] | FOLFIRI | Irinotecan (150 mg/m2) and folinic acid (200 mg/m2) followed by a bolus infusion of fluorouracil (400 mg/m2) and subsequent continuous infusion of fluorouracil (2,400 mg/m2), repeated every 2 weeks until disease progression | 36 | <80% vs. ≥80% | |
| Colorectal | mFOLFOX6 | Six cycles of mFOLFOX6, consisting of oxaliplatin (85 mg/m2) and folinic acid (200 mg/m2), followed by a bolus infusion of fluorouracil (400 mg/m2) and subsequent continuous infusion of fluorouracil (2,400 mg/m2), repeated every 2 weeks followed by maintenance therapy with oral S‐1. Reintroduction of mFOLFOX6 therapy was scheduled after four cycles of S‐1 or upon tumor progression | 30 | <79% vs. ≥79% | |
| Kobayashi 2019 [24] | Pancreas | FOLFIRINOX | Irinotecan: 180 mg/m2; oxaliplatin: 85 mg/m2; 5‐FU bolus: 400 mg/m2; 5‐FU continuous infusion: 2,400 mg/m2 | 359 |
Irinotecan: <75% vs. ≥75% Oxaliplatin: <70% vs. ≥75% 5‐FU bolus: 0% vs. >0% 5‐FU continuous infusion: <80% vs. ≥80% |
| Lee 2017 [26] | Pancreas | FOLFIRINOX | 85 mg/m2 for oxaliplatin; 180 mg/m2 for irinotecan; 400 mg/m2 for 5‐FU as a bolus and 2,400 mg/m2 for 5‐FU via continuous infusion every 2 weeks | 133 | <80% vs. ≥80% |
AUC, area under the curve; FOLFIRI, folinic acid (leucovorin), fluorouracil (5‐FU), and irinotecan; FOLFOX, folinic acid (leucovorin), fluorouracil (5‐FU), and oxaliplatin; FOLIRINOX, folinic acid (leucovorin), fluorouracil (5‐FU), irinotecan, and oxaliplatin; mFOLFOX6, modified FOLFOX (six cycles postoperative); FU, fluorouracil; NSCLC, non‐small cell lung cancer; q3w, every 3 weeks; q4w, every 4 weeks; RDI, relative dose intensity.